Boston Heart Diagnostics Awarded $1.0 Million in Tax Incentives from the Massachusetts Life Sciences Center

FRAMINGHAM, Mass., Feb. 20, 2014 /PRNewswire/ -- Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics with personal nutrition and lifestyle programs for patients with or at risk for heart disease, has received $1.0 million in additional tax incentives through the Life Sciences Tax Incentive Program. The company has pledged to create a minimum of 50 new Massachusetts jobs in 2014. Boston Heart was one of just 33 companies to receive the tax incentive through the program this year, which is jointly administered by the Massachusetts Life Sciences Center (MLSC) and the Massachusetts Department of Revenue. Excluding the latest award, Boston Heart has received more than $1.1 million in tax incentives from the MLSC program over the last three years. During that period, the company exceeded its pledge to create 102 Massachusetts full-time-equivalent (FTE) jobs, adding a total of 190 Massachusetts-based positions.

(Photo: http://photos.prnewswire.com/prnh/20110524/NE03671LOGO ) 

"Boston Heart is a Massachusetts success story and the Life Sciences Tax Incentive Program continues to be an important contributor to our achievements," said Boston Heart President and CEO, Susan Hertzberg. "These funds have helped us accelerate growth and enabled recruitment of our talented employees who are dedicated to improving the lives of patients. We continue to innovate, expand our portfolio of diagnostic and service offerings, and increase our reach in the market. We work with healthcare providers nationwide – giving them the tools they need to identify risk, individualize treatment plans, and engage patients in preventing and reversing cardiovascular disease. We greatly appreciate the support that MLSC provides in helping us to achieve our mission."

About Boston Heart Diagnostics (BostonHeartDiagnostics.com)
Boston Heart is re-inventing the role of diagnostics in cardiovascular disease (CVD), the number one cause of death in the United States. There's much more to CVD than "good" and "bad" cholesterol – that's why traditional cholesterol screens often miss those at significant risk for heart attack or stroke. In fact, individuals can still have up to a 75% residual risk for serious cardiac events after successfully lowering LDL. We work with healthcare providers to engage individuals in their own well-being and give them the tools they need to prevent or reduce their CVD risk and improve health outcomes. Applying the latest clinical research and advances in laboratory science, we integrate results from our proprietary tests and health history information with an individual's food and exercise preferences – all transformed into practical nutrition, lifestyle, and support strategies tailor-made for each person. We help people make meaningful and lasting change through the use of easy-to-understand reports, one-on-one coaching, and sustained support. Boston Heart Diagnostics is leading the charge to turn the promise of personalized medicine into a reality.

Media contact: Caroline Grossman - 781.771.5579 - [email protected]

SOURCE Boston Heart Diagnostics Corporation